EGFL7

Across TCGA pan-cancer cohorts, EGFL7 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated EGFL7 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EGFL7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EGFL7 expression acts as an unfavorable survival marker.

PDAC and LSCC are the cancer types where EGFL7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.371	0.665	.011	7	view →
LSCC	OS	Tertile	II,III,IV	0.744	0.960	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

EGFL7–PDAC (DFS)

Open the PDAC breakdown →